Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Price Performance

SENS stock opened at $0.35 on Friday. The stock’s 50 day moving average is $0.39 and its two-hundred day moving average is $0.44. Senseonics has a 52-week low of $0.32 and a 52-week high of $0.75. The company has a market capitalization of $185.44 million, a PE ratio of -2.50 and a beta of 0.79. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The business had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Analysts predict that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Trading of Senseonics

Several institutional investors have recently added to or reduced their stakes in SENS. State Board of Administration of Florida Retirement System acquired a new position in shares of Senseonics in the 1st quarter valued at about $91,000. Virtu Financial LLC acquired a new position in Senseonics in the first quarter valued at approximately $162,000. Cubist Systematic Strategies LLC grew its holdings in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.